For the first time, the World Health Organization has sanctioned use of a generic hepatitis C medicine by the United Nations and other agencies in hopes of widening access to a needed treatment.

Specifically, the WHO wants to encourage greater use of lower-cost versions of Sovaldi in dozens of countries where public health advocates say availability has been impeded by bureaucratic delays to an access plan hatched three years ago by Gilead Sciences (GILD), which sells the brand-name drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Stylish new page look, I see? Meanwhile, that’s quite a price adjustment – $3/USD per pill, down from $1,000 USD. And Mylan will still make money? Or will they be relying on the EpiPen to make up the difference?

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy